Analysis of Injectate Spread During Erector Spinae Block

December 16, 2022 updated by: Ji Hee Hong, Keimyung University Dongsan Medical Center

Comparison of the Spread Level During Thoracic Erector Spinae Plane Block Using Two Volumes of Local Anesthetics

The primary purpose of this study was to identify the ESPB spread level in the craniocaudal direction when performed at the T2 level. The secondary purpose was to determine the incidence of spread into epidural, paravertebral, intercostal, and intravascular injections with ESPB

Study Overview

Status

Completed

Conditions

Detailed Description

The ESPB requires ultrasound guidance which enables visible local anesthetic spread underneath the erector spinae muscles. The spinalis, longissimus thoracis, and iliocostalis muscles comprise the ES muscles, which run vertically along both sides of the vertebral column from the sacrum up to the skull base. The ESPB can be performed in the cervical, thoracic, and lumbar regions. Among them, upper or mid thoracic ESPB has been used more widely compared to cervical and lumbar regions. Previous cadaveric studies on the ESPB at the T5 level using computed tomography (CT) reconstruction or direct dissection demonstrated the extensive craniocaudal distribution of methylene blue ranging from T1 to T8 vertebral segments deep to the ES muscles and variable involvement of epidural, paravertebral, and intercostal spaces. The ESPB performed at the T2 level of the cadaver demonstrated an injected dye distribution ranging from C4 to T10. Also, 36% of cadavers showed the spread of an injected dye to the ventral, dorsal ramus, paravertebral space, and even the contralateral side. The exact mechanism of action of ESPB remains unclear. A recent study suggested that the analgesic effect of ESPB could be obtained by blocking the ventral and dorsal ramus of the spinal nerves by passing through the costotransverse foramen. However, in clinical practice, we can encounter highly variable clinical outcomes or sensory block after the ESPB. The study of the physical spread of the injected agent can be used to predict the clinical result and elucidate the possible mechanism of action of ESPB.

Study Type

Interventional

Enrollment (Actual)

159

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Daegu, Korea, Republic of, 42601
        • Hong ji HEE
      • Daegu, Korea, Republic of, 700712
        • Ji Hee Hong

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 78 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Cervical facet joint arthrosis
  • Cervical foraminal stenosis
  • Cervical herniated intervertebral disc
  • myofascial pain syndrome of upper back muscle

Exclusion Criteria:

  • Allergy to local anesthetics or contrast medium
  • Pregnancy
  • Prior history of cervical spine surgery
  • Coagulation abnormality

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 10 ml ESP group
ESP group using 10 ml mixture of local anesthetics and contrast medium using ultrasound and fluoroscopy
fascial plane injection using ultrasound and fluoroscopic guidance
Other Names:
  • ESP
Experimental: 20 ml ESP group
ESP group using 20 ml mixture of local anesthetics and contrast medium using ultrasound and fluoroscopy
fascial plane injection using ultrasound and fluoroscopic guidance
Other Names:
  • ESP

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
spread level in the cranio-caudal direction
Time Frame: baseline, 1 minutes after erector spinae plane block
fluoroscopic contrast medium spread level in the cranio-caudal direction
baseline, 1 minutes after erector spinae plane block

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participant showing epidural spread
Time Frame: baseline, 1 minute after erector spinae plane block
Number of participant showing epidural spread by analysis of fluoroscopic image
baseline, 1 minute after erector spinae plane block
Number of participant showing paravertebral spread
Time Frame: baseline, 1 minute after erector spinae plane block
Number of participant showing paravertebral spread by analysis of fluorosocpic image
baseline, 1 minute after erector spinae plane block
Number of participant showing intercostal spread
Time Frame: baseline, 1 minute after erector spinae plane block
Number of participant showing intercostal spread by analysis of fluoroscopic image
baseline, 1 minute after erector spinae plane block
Number of participant showing intravascular spread
Time Frame: baseline, 1 minute after erector spinae plane block
Number of participants showing intravascular spread by analysis of fluoroscopic image
baseline, 1 minute after erector spinae plane block

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 21, 2022

Primary Completion (Actual)

October 30, 2022

Study Completion (Actual)

October 30, 2022

Study Registration Dates

First Submitted

February 10, 2022

First Submitted That Met QC Criteria

March 5, 2022

First Posted (Actual)

March 15, 2022

Study Record Updates

Last Update Posted (Actual)

December 20, 2022

Last Update Submitted That Met QC Criteria

December 16, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • Keimyung University

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain

Clinical Trials on Erector spinae plane block

3
Subscribe